Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 8/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 8/20 | 0.48 |
| ▸ | PDK3 | Q15120 | 8/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 8/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871226 | 0.92 | CHRM2 (0.61) | CHRM2LMNA | |
| SCHEMBL4867648 | 0.86 | TP53 (0.48) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL4868270 | 0.85 | PDK1 (0.44) | CHRM2PDK1PDK2PDK3PDK4 | |
| SCHEMBL4869687 | 0.84 | PDK1 (0.53) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL4869649 | 0.83 | PDK1 (0.48) | PDK1PDK2PDK3PDK4CA1 | |
| SCHEMBL4870695 | 0.83 | MAPT (0.52) | PDK1PDK2PDK3PDK4LMNA | |
| SCHEMBL4866075 | 0.81 | TP53 (0.59) | LMNA | |
| SCHEMBL4871155 | 0.80 | PDK1 (0.51) | PDK1PDK2PDK3PDK4LMNA | |
| SCHEMBL4870081 | 0.80 | LMNA (0.53) | LMNA | |
| SCHEMBL4863677 | 0.79 | PDK1 (0.53) | PDK1PDK2PDK3PDK4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | CHRM2 396/4885PDK1 2625/4885PDK2 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.